Eric Lefkofsky co-founded a Chicago-based technology company, Tempus, in 2015 with aims to help physicians make decisions and provide personalized cancer care by providing them with an ever-growing library of molecular and clinical data. Tempus received $80 million in this latest round of funding, which brought its value to approximately $1.1 billion and in doing so gave the new company “unicorn status”. This label is a very significant accomplishment for a Chicago startup which reflects how the company is growing at a quick steady rate and has the means to increase its reach and impact on cancer patients.
Tempus is focused on unlocking the mysteries of cancer through data by making it easily searchable and comparable. The company has about 400 employees and is hiring around 30 more each month. These employees collect data and digitize data such as doctor’s handwritten notes to make them accessible. As the company’s employee base grew and its value grew giving it this “unicorn status” the data in its library grew and continues to grow.
Tempus is creating a digital tool that allows physicians to reference data on patients’ cancer tumors, their genetic make-up, and the treatment they responded to when making treatment decisions. The company and its co-founder have network relationships within the health care system and cancer-fighting bodies that are working toward finding the best ways to treat cancer patients. The database Tempus is actively creating and network it has in the health care system is influential and their new “unicorn status” will fund their continued growth, empowering them to help empowers them to help more patients.
To Know More Click Here